Dr. Andrea Cox

Dr. Andrea L. Cox is a professor of Internal Medicine at the Johns Hopkins University School of Medicine in the Division of Infectious Diseases and is a member of the Johns Hopkins Kimmel Cancer Center. She holds joint appointments in Oncology and at the Johns Hopkins Bloomberg School of Public Health, in Molecular Microbiology and Immunology. She is an internationally recognized leader in studies of immune responses in immunocompetent and immunocompromised patient populations to viral infections and vaccines against them, including SARS-Co-V-2 (the virus that causes COVID-19), HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). Dr. Cox earned her Ph.D. in chemistry from the University of Virginia, where she characterized peptides that drive T cell responses. She then earned her M.D. and completed internal medicine residency and infectious disease fellowship training at Johns Hopkins. She leads the largest prospective cohort study of acute HCV infection, designed to enable detailed molecular analysis of HCV transmission, host immune responses, and virus sequence evolution. She co-led the first prophylactic HCV vaccine trial in individuals at risk of HCV infection. She leads a multidisciplinary international team investigating HCV-specific immune responses to improve vaccine development against HCV, is the lead immunologist on a clinical trial of HBV vaccines in people living with HIV, and co-leads a large team investigating immune responses to COVID-19 infection and vaccines. In addition to her research on viral infections and vaccines, Dr. Cox is actively involved in clinical care of patients with HCV, HIV, and HBV infections. Dr. Cox serves as the director of the Medical Scientist Training Program. A teacher, advisor, and mentor of physician-scientists and scientists, Dr. Cox mentors Ph.D. students in the Johns Hopkins Cellular and Molecular Medicine, Molecular Microbiology and Immunology, and the Immunology graduate training programs.

Dr. Cox is rated as an Experienced provider by MediFind in the treatment of Multisystem Inflammatory Syndrome in Children (MIS-C). Her top areas of expertise are Hepatitis C, Hepatitis, Severe Acute Respiratory Syndrome (SARS), and COVID-19.

Her clinical research consists of co-authoring 175 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Multisystem Inflammatory Syndrome in Children (MIS-C).